KR20260006688A - 폴리 테일 및 폴리 캡 mRNA 그리고 그의 용도 - Google Patents

폴리 테일 및 폴리 캡 mRNA 그리고 그의 용도

Info

Publication number
KR20260006688A
KR20260006688A KR1020257041790A KR20257041790A KR20260006688A KR 20260006688 A KR20260006688 A KR 20260006688A KR 1020257041790 A KR1020257041790 A KR 1020257041790A KR 20257041790 A KR20257041790 A KR 20257041790A KR 20260006688 A KR20260006688 A KR 20260006688A
Authority
KR
South Korea
Prior art keywords
mrna
modified
poly
cap
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257041790A
Other languages
English (en)
Korean (ko)
Inventor
샤오 왕
홍위 천
아비셰크 아디탐
졘팅 궈
?컷? 궈
Original Assignee
더 브로드 인스티튜트, 인코퍼레이티드
매사추세츠 인스티튜트 오브 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 브로드 인스티튜트, 인코퍼레이티드, 매사추세츠 인스티튜트 오브 테크놀로지 filed Critical 더 브로드 인스티튜트, 인코퍼레이티드
Publication of KR20260006688A publication Critical patent/KR20260006688A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020257041790A 2022-01-18 2023-01-18 폴리 테일 및 폴리 캡 mRNA 그리고 그의 용도 Pending KR20260006688A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263300602P 2022-01-18 2022-01-18
US63/300,602 2022-01-18
KR1020247025804A KR20240144777A (ko) 2022-01-18 2023-01-18 폴리 테일 및 폴리 캡 mRNA 그리고 그의 용도
PCT/US2023/060852 WO2023141474A1 (en) 2022-01-18 2023-01-18 Poly-tailed and poly-capped mrna and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247025804A Division KR20240144777A (ko) 2022-01-18 2023-01-18 폴리 테일 및 폴리 캡 mRNA 그리고 그의 용도

Publications (1)

Publication Number Publication Date
KR20260006688A true KR20260006688A (ko) 2026-01-13

Family

ID=85381073

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257041790A Pending KR20260006688A (ko) 2022-01-18 2023-01-18 폴리 테일 및 폴리 캡 mRNA 그리고 그의 용도
KR1020247025804A Pending KR20240144777A (ko) 2022-01-18 2023-01-18 폴리 테일 및 폴리 캡 mRNA 그리고 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247025804A Pending KR20240144777A (ko) 2022-01-18 2023-01-18 폴리 테일 및 폴리 캡 mRNA 그리고 그의 용도

Country Status (8)

Country Link
US (1) US20240392311A1 (https=)
EP (2) EP4466074A1 (https=)
JP (2) JP2025503730A (https=)
KR (2) KR20260006688A (https=)
CN (2) CN121718542A (https=)
AU (2) AU2023209862A1 (https=)
CA (1) CA3248956A1 (https=)
WO (1) WO2023141474A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025519910A (ja) * 2022-06-24 2025-06-26 ザ・ブロード・インスティテュート・インコーポレイテッド キャップされた環状ｒｎａ分子を調製するための組成物及び方法
WO2025076085A1 (en) * 2023-10-02 2025-04-10 Convergence Bio, Inc. Multi-terminus polya polynucleotides
WO2025111430A1 (en) * 2023-11-21 2025-05-30 Prime Medicine, Inc. CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL
WO2025147660A2 (en) * 2024-01-04 2025-07-10 Trilink Biotechnologies, Llc Modified rna for increasing protein expression
WO2025175176A1 (en) * 2024-02-14 2025-08-21 Modernatx, Inc. Synthetic nucleic acids and methods of using the same for improved polypeptide production
WO2025180432A1 (zh) * 2024-02-28 2025-09-04 图维生物医药科技(苏州)有限公司 一种用于rna加帽的酶及其反应体系
WO2025217126A1 (en) * 2024-04-09 2025-10-16 Convergence Bio, Inc. Polynucleotides, 3' chain terminating tails, ligation and uses thereof
WO2025217135A1 (en) * 2024-04-09 2025-10-16 Convergence Bio, Inc. Rna ligation methods and products

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53669A (fr) * 2018-09-20 2021-07-28 Modernatx Inc Compositions et procédés d'administration d'acides nucléiques
BR112021023411A2 (pt) 2019-05-22 2022-02-01 Massachusetts Inst Technology Composições e métodos de rna circular
JP2024518546A (ja) * 2021-05-12 2024-05-01 ザ ブロード インスティテュート，インコーポレーテッド 修飾されたｍＲＮＡ、修飾された非コードＲＮＡ、およびその使用

Also Published As

Publication number Publication date
KR20240144777A (ko) 2024-10-02
EP4737574A2 (en) 2026-05-06
AU2025252534A1 (en) 2025-11-06
EP4466074A1 (en) 2024-11-27
CN119095964A (zh) 2024-12-06
US20240392311A1 (en) 2024-11-28
CA3248956A1 (en) 2023-07-27
AU2023209862A1 (en) 2024-08-15
CN121718542A (zh) 2026-03-24
JP2025503730A (ja) 2025-02-04
WO2023141474A9 (en) 2023-10-26
JP2026016516A (ja) 2026-02-03
WO2023141474A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
EP4737574A2 (en) Poly-tailed and poly-capped mrna and uses thereof
US20240277872A1 (en) Modified mrna, modified non-coding rna, and uses thereof
US20230265431A1 (en) Oligonucleotides, manufacturing method for same, and target rna site-specific editing method
KR102418185B1 (ko) 단일 가닥 rna-편집 올리고뉴클레오타이드
AU2020233404A1 (en) Circular polyribonucleotides and pharmaceutical compositions thereof
WO2021060527A1 (ja) オリゴヌクレオチド及び標的ｒｎａの部位特異的編集方法
JP2021519071A (ja) シュードウリジン化のための核酸分子
US20250297246A1 (en) Modified prime editing guide rnas
JP7333508B2 (ja) オリゴヌクレオチド、その製造方法及び標的ｒｎａの部位特異的編集方法
US20250129400A1 (en) Compositions and methods for preparing capped circular rna molecules
KR20240035752A (ko) 원형 폴리리보뉴클레오티드의 농축 방법
WO2025043082A2 (en) Compositions and methods to improve rna properties using base, phosphodiester linkage, sugar backbone, and cap modifications
CN118076741A (zh) 修饰的mRNA、修饰的非编码RNA及其用途
WO2025231018A2 (en) Therapeutic compositions and methods for producing and using the same
WO2025170909A1 (en) Nucleic acids with region-specific modifications and methods of making the same
WO2026006213A1 (en) Methods of making modified branched rnas
EP3696270A1 (en) Regulation of nucleic acid molecule expression

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)